<DOC>
	<DOCNO>NCT01311518</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability two active dos RGN-352 ( thymosin beta 4 , Tβ4 , Injectable Solution ) patient acute myocardial infarction receive percutaneous coronary intervention angioplasty without stent placement . Approximately 75 subject randomize receive one two RGN-352 dos 1200 mg , 450 mg , placebo , administer iv iv push daily first 3 consecutive day weekly 4 week .</brief_summary>
	<brief_title>A Study Safety Efficacy Injectable Thymosin Beta 4 Treating Acute Myocardial Infarction</brief_title>
	<detailed_description>This double-blind , placebo control , parallel-group , dose find study . Eligible subject randomize receive one two dose RGN-352 match placebo equal allocation ratio ( i.e. , 1:1:1 ) . Approximately 75 subject randomize study treatment achieve least 60 evaluable subject 20 25 subject per group . Subjects randomized receive one two RGN-352 dos 1200 mg , 450 mg , placebo , administer iv iv push daily first 3 consecutive day weekly 4 consecutive week . Study subject undergo cardiac angiography ass initial coronary artery patency Thrombolysis In Myocardial Infarction flow grade pre- post-percutaneous coronary intervention ( PCI ) angioplasty . A total 7 dos administrated treatment period . The first dose either RGN-352 placebo administer randomized subject follow PCI angioplasty specifically within 30 minute balloon deflation , 2 dos . The remain 4 dos give weekly 4 consecutive week . Follow-up Months 2 , 4 , 6 .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Male female subject 2 . Negative urine pregnancy test Screening 3 . An electrocardiogram 4 . First acute anterior MI 5 . Baseline angiography 6 . Onset chest pain symptom initial PCI angioplasty time 2 6 hour 7 . Written inform consent reviewed sign subject legally authorize representative 1 . Intention treat subject thrombolytic therapy follow assertion Thrombolysis In Myocardial Infarction ( TIMI ) flow 0 1 qualify angiogram 2 . History Myocardial infarctionI congestive heart failure 3 . Nonatherosclerotic etiology acute myocardial infarction 4 . Cardiogenic shock ( systolic blood pressure &lt; 90 despite adequate leave ventricle filling pressure require catecholamine ) hemodynamic instability baseline 5 . Further transcatheter surgical revascularization , e.g. , coronary artery bypass graft plan per baseline angiogram 6 . Lactating woman 7 . Past present evidence malignancy 8 . Women menarche complete menopause , surgically sterilize ( bilateral tubal ligation hysterectomy ) , partner documented sterility ( include vasectomy ) , use adequate contraception ( combine hormonal doublebarrier method contraception , sexual abstinence method contraception acceptable study ) 9 . Ongoing infectious disease include human immunodeficiency virus ( HIV ) hepatitis 10 . Clinically significant respiratory , renal , metabolic , liver , central nervous system comorbid disease , except current cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Thymosin Beta 4</keyword>
	<keyword>Thymosin β4 ( Tβ4 ) Injectable Solution</keyword>
	<keyword>RGN-352</keyword>
</DOC>